Abstract
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.
| Original language | English |
|---|---|
| Pages (from-to) | 175-185 |
| Number of pages | 11 |
| Journal | Cancer Letters |
| Volume | 248 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 18 2007 |
Keywords
- Breast cancer
- Primary chemotherapy
- Primary endocrine therapy
- Primary targeted therapy
ASJC Scopus subject areas
- Cancer Research
- Molecular Biology
- Oncology
Fingerprint Dive into the research topics of 'Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives'. Together they form a unique fingerprint.
Cite this
Guarneri, V., Frassoldati, A., Giovannelli, S., Borghi, F., & Conte, P. (2007). Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives. Cancer Letters, 248(2), 175-185. https://doi.org/10.1016/j.canlet.2006.07.001